StockData
Avalyn Pharma Inc. logo

Avalyn Pharma Inc. (AVLN) company profile

AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.92−1.84 (-6.18%)

Close on Nov 17, 2026Market cap $1.24BP/E –Yield –

About Avalyn Pharma

Pharmaceutical Preparations, SIC 2834

Avalyn Pharma Inc. is listed on Nasdaq under the ticker AVLN, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Avalyn Pharma Inc.
Headquarters
Boston, MA
Address
105 W First St. 02127
Phone
(206) 707-0340
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
AVLN
Exchange
Nasdaq
IPO date
Apr 30, 2026
Shares outstanding
44M, Aug 31, 2026
Filer category
<br>Emerging growth company
SEC CIK
1540171
CUSIP
05348Y105
ISIN
US05348Y1055
FIGI
BBG003M9S3Z4
Share class FIGI
BBG003M9S400
EIN
45-2463191

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Lyn BaranowskiChief Executive Officer, Director–
Adam H. GoldenGeneral Counsel–
Melissa RhodesChief Operating Officer–
Douglas R. CarlsonChief Financial Officer–
Howard LazarusChief Medical Officer–
Robert J. MeyerDirector–
Heather D. TurnerDirector–
Jon CongletonDirector–
Kate HavilandDirector–
Erin LavelleDirector–
Jill CarrollDirector1,419,298
David Matthew FriedmanDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 30, 2026
Offer price
$18.00
Securities offered
16,666,667
Gross proceeds
$300.00M
Exchange
Nasdaq
Lock-up ends (est.)
Oct 27, 2026

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 30, 2026IPOInitial public offering priced (424B4 prospectus)
Apr 27, 2026ListingRegistration of securities on an exchange (Form 8-A)
May 24, 2017Name changeName changed from Genoa Pharmaceuticals, Inc. to Avalyn Pharma Inc.

See a number that looks wrong?